The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Manoj Sunil Chawda
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts more than Nifty Microcap 250 and 7.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Manoj Sunil Chawda, part of the promoter group of Oxygenta Pharmaceutical Limited, has sold 10,12,800 equity shares (2.74% of the company's voting capital) through a Share Purchase Agreement dated September 30, 2024, with the transaction completed on April 22, 2025. Following this sale, his holding has dropped from 15,82,500 shares (4.28%) to 5,69,700 shares (1.54%) of the company. The shares are listed on BSE (Scrip Code: 524636), and the total equity share capital remains unchanged at 3,69,83,500 shares of Rs. 10 each. No encumbrances, warrants, or convertible securities are involved in this transaction.
This is a notable promoter exit, with the promoter group member reducing his stake by more than half. For shareholders, this signals continued promoter selling and may raise concerns about insider confidence in the stock, potentially putting short-term pressure on the share price.